Opus Genetics (IRD) Interest Coverage Ratio (2020 - 2026)

Opus Genetics (IRD) posted quarterly Interest Coverage Ratio of 143.64 for Q1 2026, down 72.83% quarter-over-quarter from 83.11 in Q3 2025.

Analysis

Opus Genetics (IRD) Interest Coverage Ratio (2020 - 2026) Analysis & Trends

Opus Genetics (IRD) has reported Interest Coverage Ratio for 14 consecutive years, with 143.64 the latest figure, recorded in Q1 2026.

In Q1 2026, Interest Coverage Ratio changed N/A year-over-year to 143.64; the TTM figure through Mar 2026 stood at 215.17 (changed N/A YoY), while the FY2025 annual figure was 0.97, changed N/A from the prior year.
Interest Coverage Ratio eased to 143.64 in Q1 2026 per IRD's latest filing, from 83.11 in the prior quarter.
Across five years, Interest Coverage Ratio topped out at 83.11 in Q3 2025 and bottomed at 1301.6 in Q1 2022.
Historically, Interest Coverage Ratio has averaged 690.71 across 3 years, with a median of 689.07 in 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Interest Cover (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	117.59
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-493.00
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-21.24
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	8.18
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	2.82
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	1.42
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-0.08
10	Opus Genetics	446.86 Mn	358.05 Mn	-	-

Historic Data

Download Data